VTD方案治疗多发性骨髓瘤临床分析  

Clinical analysis of VTD regimen in the treatment of multiple myeloma

作　　者：杨宇娟[1] 王倩[1] 付杰[1] 李晓林[1] Yang Yujuan;Wang Qian;Fu Jie;Li Xiaolin(Department of Hematology,the Central Hospital of Xuzhou City 221000)

机构地区：[1]徐州市中心医院血液科,221000

出　　处：《中国社区医师》2018年第30期55-56,58,共3页Chinese Community Doctors

摘　　要：目的:探讨硼替佐米、沙利度胺及地塞米松(VTD)方案治疗多发性骨髓瘤(MM)的临床疗效和不良反应。方法:收治多发性骨髓瘤患者40例,所有患者均采用VTD方案化疗。结果:初治MM患者34例,治疗总体反应率88.2%(30/34)。其中CR+VGPR 61.8%(21/34),采用其他化疗方案治疗后复发的6例MM患者对VTD方案总反应率66.7%,差异无统计学意义(P>0.05)。结论:MM患者对VTD方案耐受性良好,周围神经病变是治疗过程中值得重视的不良反应,仍需开发新的治疗方法进一步延长患者总生存率,提高患者生活质量。Objective:To investigate the clinical efficacy and side effects of bortezomib,thalidomide and dexamethasone(VTD)regimen in the treatment of multiple myeloma(MM).Methods:40 patients with multiple myeloma were selected,all patients were treated with VTD regimen.Results:There were 34 cases of newly diagnosed MM patients,the overall response rate was 88.2%(30/34),of which,CR+VGPR was 61.8%(21/34).The total response rate of 6 MM patients with relapse after treatment with other chemotherapy regimens to VTD was 66.7%,the difference was not statistically significant(P>0.05).Conclusion:The tolerance of MM patients to VTD was good,peripheral neuropathy was a serious adverse reaction during treatment,we still need to develop new therapies to further extend the overall survival of patients and improve their quality of life.

关 键 词：多发性骨髓瘤 硼替佐米 沙利度胺 地塞米松 

分 类 号：R733.3[医药卫生—肿瘤]